Reviving Intervertebral Discs: Treating Degeneration Using Advanced Delivery Systems

Hong Zhang,Xiaorong Yang,Yiheng Huang,Yue Li,Quan Hu,Qiaolin Wei,Weixing Xu,Weiguo Ding,Yong Guo,Jia-Wei Shen
DOI: https://doi.org/10.1021/acs.molpharmaceut.3c00579
2024-01-01
Molecular Pharmaceutics
Abstract:Intervertebral disc degeneration (IVDD) is commonly associated with many spinal problems, such as low back pain, and significantly impacts a patient's quality of life. However, current treatments for IVDD, which include conservative and surgical methods, are limited in their ability to fully address degeneration. To combat IVDD, delivery-system-based therapy has received extensive attention from researchers. These delivery systems can effectively deliver therapeutic agents for IVDD, overcoming the limitations of these agents, reducing leakage and increasing local concentration to inhibit IVDD or promote intervertebral disc (IVD) regeneration. This review first briefly introduces the structure and function of the IVD, and the related pathophysiology of IVDD. Subsequently, the roles of drug-based and bioactive-substance-based delivery systems in IVDD are highlighted. The former includes natural source drugs, nonsteroidal anti-inflammatory drugs, steroid medications, and other small molecular drugs. The latter includes chemokines, growth factors, interleukin, and platelet-rich plasma. Additionally, gene-based and cell-based delivery systems are briefly involved. Finally, the limitations and future development of the combination of therapeutic agents and delivery systems in the treatment of IVDD are discussed, providing insights for future research.
What problem does this paper attempt to address?